Jennifer Trowbridge of JAX seeks to thwart the mutations and inflammation that accumulate in aging bone marrow to maintain production of healthy blood cells and reduce blood cancer risk.
Erythroid-specific deletion of Bcl11a expression corrects sickle cell disease (SCD) in mice, suggesting that BCL11a-targeted therapies may be efficacious in SCD patients.